Success Metrics

Clinical Success Rate
94.7%

Based on 18 completed trials

Completion Rate
95%(18/19)
Active Trials
4(17%)
Results Posted
11%(2 trials)
Terminated
1(4%)

Phase Distribution

Ph phase_3
1
4%
Ph not_applicable
4
17%
Ph phase_2
1
4%
Ph phase_4
7
29%
Ph phase_1
1
4%

Phase Distribution

1

Early Stage

1

Mid Stage

8

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
1(7.1%)
Phase 2Efficacy & side effects
1(7.1%)
Phase 3Large-scale testing
1(7.1%)
Phase 4Post-market surveillance
7(50.0%)
N/ANon-phased studies
4(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.7%

18 of 19 finished

Non-Completion Rate

5.3%

1 ended early

Currently Active

4

trials recruiting

Total Trials

24

all time

Status Distribution
Active(4)
Completed(18)
Terminated(1)
Other(1)

Detailed Status

Completed18
Active, not recruiting2
Recruiting2
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
24
Active
4
Success Rate
94.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.1%)
Phase 21 (7.1%)
Phase 31 (7.1%)
Phase 47 (50.0%)
N/A4 (28.6%)

Trials by Status

completed1875%
active_not_recruiting28%
unknown14%
recruiting28%
terminated14%

Recent Activity

4 active trials
Showing 5 of 24
recruiting

Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination

NCT06635525
completedphase_4

Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease

NCT06508437
completedphase_4

Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination

NCT01499914
active_not_recruiting

Vaccine Responses in Cancer

NCT06605625
recruitingphase_4

Study of Immune Responses to Influenza Vaccination

NCT03346772
View all 24 trials

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT06635525

Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination

Recruiting
NCT06508437Phase 4

Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease

Completed
NCT01499914Phase 4

Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination

Completed
NCT06605625

Vaccine Responses in Cancer

Active Not Recruiting
NCT03346772Phase 4

Study of Immune Responses to Influenza Vaccination

Recruiting
NCT06725927Phase 4

Vaccination Against Influenza Pre-discharge in Heart Failure

Active Not Recruiting
NCT03061955

Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

Completed
NCT05783713

Evaluation of the Effectiveness of a Flu Vaccination Campaign for Healthcare Workers of a Teaching Hospital: a Pre-post Study

Completed
NCT05481801

Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-2)

Completed
NCT04059991

Antibodies in Repeated Influenza Vaccination (ARIVA) Study

Completed
NCT03478254

Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).

Completed
NCT04188483Not Applicable

Effect of Selenium Supplementation on Influenza Vaccination

Completed
NCT03590808Not Applicable

Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor

Completed
NCT03654937Phase 4

Immune Response and Risk of Side Effects After Influenza Vaccination in Athletes

Completed
NCT02900209

Influenza Vaccination and COPD Phenotypes

Completed
NCT01666535Not Applicable

Infliximab IBD Influenza Vaccine Study

Completed
NCT02296359

Vaccination Response in Individual Monozygotic Twins

Terminated
NCT00639418

A Study to Describe Pediatric Influenza Vaccine Coverage

Completed
NCT00877396Phase 4

Hutterite Influenza Prevention Study

Completed
NCT00395174Phase 3

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
24